Copyright  2018 Advantagene, Inc.  All rights reserved. Made by AFP.    Terms of use | Privacy policy

More than 4,000 children are diagnosed with a brain tumor each year. Malignant brain tumors are the second most common form of childhood cancer, and are the leading cause of cancer-related death for children under 10 years old and second leading cause of cancer-related death in all children under 20 years old. Similar to adult brain tumors, pediatric brain tumors are difficult to treat and a diagnosis is not only physically overwhelming for patients but emotionally draining for families.

We have completed enrollment in a Phase 1 study in this indication to evaluate the administration of GMCI in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective was to determine if this approach is safe and can be effectively delivered without disturbing standard therapy.

Principal Investigator

Mark W Kieran, MD, PhD

Director, Pediatric Medical Neuro-Oncology, Dana Farber Cancer Institute/Boston Children’s Hospital, Associate Professor of Pediatrics, Harvard Medical School.  


For more information on this study , Click

Pediatric Glioma